Here are 1-3 brief analogies for Indivior Pharmaceuticals:

• Indivior is like Eli Lilly for opioid use disorder treatment.
• It's the Gilead Sciences for opioid dependence.
• Think of it as the Novo Nordisk for addiction medicine.

• SUBLOCADE injection: An injectable medication for the treatment of opioid dependence.
• SUBOXONE sublingual film: A film formulation for sublingual use to treat opioid dependence.
• SUBOXONE sublingual tablet: A tablet formulation for sublingual use to treat opioid dependence.
• SUBUTEX sublingual tablet: A tablet formulation for sublingual use, often containing buprenorphine, for opioid dependence treatment.

The company Indivior Pharmaceuticals (INDV) primarily sells its buprenorphine-based prescription drugs to pharmaceutical wholesalers and distributors, who then supply pharmacies, hospitals, and clinics. Therefore, Indivior's major customers are other companies rather than individuals. Based on the standard distribution channels for prescription pharmaceuticals, particularly in its key markets, its major customers are expected to be the largest pharmaceutical wholesalers.

Here are the major customer companies:

• McKesson Corporation (MCK)
• Cencora, Inc. (ABC)
• Cardinal Health, Inc. (CAH)

Joe Ciaffoni, Chief Executive Officer

Joe Ciaffoni was appointed Chief Executive Officer of Indivior in May 2025, having previously served as a Non-Executive Director since December 2024. He is an accomplished public company CEO with over 30 years of experience in the pharmaceutical and biotech industries, leading global and U.S. organizations across various therapeutic areas. Prior to joining Indivior, Mr. Ciaffoni served as President and CEO of Collegium Pharmaceutical. His previous leadership roles include senior positions at Endo International, Biogen, and Shionogi Inc.

Ryan Preblick, Chief Financial Officer

Ryan Preblick has been the Chief Financial Officer of Indivior Pharmaceuticals, Inc. since November 2020, after serving as Interim CFO earlier that year. He has held senior roles in Indivior's global finance and commercial operations since 2012. His background includes financial leadership at Honeywell International and over a decade at Altria Corporation, where he held finance leadership roles of increasing responsibility. He also served as Finance Controller for the North America Pharmaceutical Business at Reckitt Benckiser Pharmaceutical.

Dr. Christian Heidbreder, Chief Scientific Officer

Dr. Christian Heidbreder has served as Indivior's Chief Scientific Officer since the company's formation. He brings over 35 years of experience in the neurosciences, having authored more than 500 peer-reviewed publications. Dr. Heidbreder has held positions of increasing responsibility at SmithKline Beecham's Neuroscience Department, GSK's R&D Centre of Excellence for Drug Discovery, Altria's Health Sciences Department, and Reckitt Benckiser. He was also formerly the Global R&D Director at Reckitt Benckiser Pharmaceuticals, Inc.

Jeffrey Burris, Chief Legal Officer

Jeffrey Burris serves as the Chief Legal Officer at Indivior. While detailed background information beyond his current role is not extensively available, his position indicates leadership over the company's legal affairs.

Kevin L. Espinoza, Chief Integrity and Compliance Officer

Kevin L. Espinoza was appointed as Indivior's Chief Integrity and Compliance Officer in October 2025. He joined Indivior in August 2023 as U.S. Integrity and Compliance Officer and Global Sanctions Officer. Mr. Espinoza has over 25 years of experience in the pharmaceutical and medical device industries, with more than 20 years in compliance leadership roles. His previous roles include Chief Compliance Officer at Kaleo Pharmaceuticals, Senior Vice President of Compliance at Boston Scientific, and Chief Compliance Officer at BTG.

Indivior Pharmaceuticals (symbol: INDV) faces several key business risks, primarily stemming from its history of litigation, intense competition for its core products, and ongoing regulatory and pricing pressures.

1. Litigation and Regulatory Scrutiny

Indivior has a history of costly and extensive litigation, including antitrust multi-district litigation related to its flagship product, SUBOXONE. While the company reached an agreement in August 2023 to resolve claims by the end payor class for $30 million, it still carries a provision of $188 million for the multi-district litigation (MDL). Additionally, the company is subject to a class-action lawsuit filed in August 2024, alleging management overstated its ability to forecast the negative impact of certain legislation and the financial prospects of SUBLOCADE, PERSERIS, and OPVEE. Past settlements include a $300 million agreement in 2021 for falsely and aggressively marketing Suboxone, which allegedly resulted in improper use of state Medicaid funds. In 2020, Indivior also agreed to a $600 million settlement with the federal government for its role in a scheme to maintain Medicaid formulary coverage for Suboxone by misleading officials about its dangers to children. These legal battles are not only financially burdensome but also divert management's attention from core business activities. Furthermore, Indivior is required to comply with a Corporate Integrity Agreement with the U.S. Department of Health and Human Services Office of Inspector General, adding a layer of regulatory scrutiny that can constrain operational flexibility.

2. Intense Competition and Product Reliance

Indivior operates in a highly competitive market for opioid dependence treatment. Its revenue heavily relies on a limited portfolio of products, primarily SUBLOCADE and SUBOXONE Film, making it vulnerable to market fluctuations and competitive pressures. SUBOXONE has already experienced a decline in market share and revenue due to generic competition. While some patents for SUBOXONE extend to March 26, 2030, generic alternatives are already available or anticipated, further intensifying competitive challenges. SUBLOCADE, a key growth driver for the company, faces increasing competition from rival long-acting injectable therapies, such as Brixadi (buprenorphine extended-release injection), which gained FDA approval in 2023. There is a risk that SUBLOCADE's adoption could stall below expectations due to market saturation or challenges in patient and physician uptake. The discontinuation of PERSERIS due to financial viability concerns further underscores the risks associated with product reliance and market competition.

3. Regulatory and Pricing Pressures

The pharmaceutical industry is a highly regulated environment, and Indivior is susceptible to changes in healthcare laws and policies. There is an increasing focus on drug pricing transparency and cost-containment measures by government and private payors, which could lead to reduced reimbursement rates for Indivior's products. These pressures may result in lower product utilization, decreased sales, and challenges in maintaining favorable pricing strategies, directly impacting the company's profitability and growth prospects.

The clear emerging threat for Indivior Pharmaceuticals is the recent market entry and increasing adoption of Brixadi (buprenorphine extended-release injection) by Braeburn Pharmaceuticals. Approved by the FDA in May 2023, Brixadi offers both weekly and monthly dosing options, directly competing with Indivior's key growth product, SUBLOCADE (monthly buprenorphine extended-release injection), in the long-acting injectable market for opioid use disorder treatment. This introduces a significant new competitive pressure for market share and revenue in Indivior's core segment.

Indivior Pharmaceuticals (NASDAQ: INDV) operates in significant addressable markets for its main products and pipeline. The company primarily focuses on treatments for Opioid Use Disorder (OUD) with its key products SUBLOCADE and SUBOXONE, and also has a pipeline focused on schizophrenia.

Opioid Use Disorder (OUD) Treatment Market

The global market for opioid use disorder treatment is substantial and growing. In 2025, the global opioid use disorder treatment market was valued between approximately USD 3.92 billion and USD 5.90 billion, with projections indicating growth to a range of USD 9.27 billion to USD 15.32 billion by 2034 or 2035, at a compound annual growth rate (CAGR) between 9.7% and 11.18%.

For the U.S. market specifically, the opioid use disorder market size was estimated at USD 3.37 billion in 2025 and is projected to reach around USD 9.48 billion by 2035, growing at a CAGR of 10.9%. North America held a significant share of the global OUD market, accounting for 69% in 2024 and 77.59% in 2025.

• SUBLOCADE: Indivior's SUBLOCADE, a buprenorphine extended-release injection for subcutaneous use, generated global net sales of $856 million in 2025. The net revenue for SUBLOCADE is projected to be in the range of $905 million to $945 million for 2026.
• SUBOXONE: The global market size for medications containing the buprenorphine/naloxone combination, which includes SUBOXONE, was valued at USD 6.78 billion in 2024 and is projected to reach USD 10.38 billion by 2035, at a CAGR of 3.95%. The broader Suboxone market is estimated to be valued at USD 7.4 billion in 2026 and is expected to reach USD 9.6 billion by 2033, exhibiting a CAGR of 4.1%.

Schizophrenia Treatment Market

Indivior's pipeline includes a focus on schizophrenia. The global schizophrenia treatment market is also substantial. It was valued at approximately USD 7.97 billion in 2024 and is projected to grow to a range of USD 9.83 billion by 2032 to USD 22.8 billion by 2035, with various reports indicating CAGRs between 2.65% and 8.1%. In 2026, the global schizophrenia treatment market size is estimated to be between US$8.8 billion and USD 12.45 billion.

For the U.S. region, the schizophrenia market size was approximately USD 5,749.0 million in 2022. In 2025, the U.S. schizophrenia treatment market is estimated to be valued at USD 4.2 billion and is anticipated to reach USD 7.8 billion by 2035, growing at a CAGR of 6.3%. North America held the largest revenue share in the schizophrenia drugs market in 2024.

Indivior Pharmaceuticals (INDV) is expected to drive future revenue growth over the next 2-3 years through several key strategies:

1. Accelerated SUBLOCADE Growth: The company's flagship product, SUBLOCADE, a long-acting injectable for opioid use disorder, is projected to be the primary revenue growth engine. Indivior anticipates accelerating U.S. SUBLOCADE dispense unit growth to the mid-teens in 2026 from 7% in 2025, with expected net revenue for SUBLOCADE in the range of $905 million to $945 million in 2026, representing an 8% growth at the midpoint over 2025. Recent FDA label changes in February 2026, including a rapid initiation protocol and alternative injection sites, are expected to further broaden patient access and drive increased adoption.

2. Enhanced Commercial Execution and Market Penetration: Indivior is focusing on improving its commercial strategies to expand SUBLOCADE's reach. Efforts include refining field force messaging, enhancing commercial channel productivity, boosting patient activation, and improving policy engagement. There is a particular emphasis on increasing SUBLOCADE prescriptions originating from commercial insurance plans, an area with significant untapped potential as only 25% of prescriptions currently come from these plans despite 60% of insured patients being covered by them.

3. Strategic Acquisitions and Pipeline Expansion: Looking beyond its current portfolio, Indivior's "Phase III - Breakout" strategy, planned for late 2026 and beyond, involves leveraging its strengthened financial position to acquire new growth drivers. The company maintains a pipeline of product candidates aimed at expanding its heritage in opioid use disorder treatment and potentially addressing other substance use disorders, such as alcohol use disorder and cannabis use disorder.

4. Focus on the U.S. Opioid Use Disorder Market: Indivior is sharpening its U.S.-centric strategy for opioid use disorder (OUD), which generated 85% of its net revenues in 2025. This concentrated focus positions the company to capitalize on the increasing prevalence of substance use disorder globally, especially opioids, providing a robust market backdrop for its specialized treatments.

Share Repurchases

• Indivior Pharmaceuticals authorized a new $400 million share repurchase program on February 26, 2026.
• On July 25, 2024, the company announced a new share repurchase program for up to $100 million, which was expected to be completed over six months, immediately following an expedited completion of a prior $100 million program initiated in November 2023.
• In March 2026, Indivior Pharmaceuticals planned to use up to approximately $75 million from the proceeds of a convertible senior notes offering to repurchase shares.

Share Issuance

• In March 2026, Indivior Pharmaceuticals completed an upsized private offering of $450 million in 0.625% convertible senior unsecured notes due March 15, 2031, which are convertible into cash and/or shares of its common stock.

Outbound Investments

• Indivior acquired Opiant Pharmaceuticals in 2023.

Capital Expenditures

• In the fourth quarter of 2025, Indivior Pharmaceuticals Inc. invested $24.0 million in capital expenditures.
• For the full year 2025, capital expenditures consumed most of the operating cash flow, leading to a negative free cash flow of $93.0 million.
• For 2026, Indivior expects to generate approximately $300 million in cash flow from operations, with capital deployment priorities including managing debt and opportunistic share repurchases.